$BRKR
BRUKER CORP

2024 Q3 Form 10-Q Financial Statement

#000095017024094832 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $864.4M $800.7M
YoY Change 16.37% 17.42%
Cost Of Revenue $445.6M $416.1M
YoY Change 23.78% 21.88%
Gross Profit $418.8M $384.6M
YoY Change 9.4% 12.95%
Gross Profit Margin 48.45% 48.03%
Selling, General & Admin $229.9M $221.3M
YoY Change 29.45% 24.4%
% of Gross Profit 54.89% 57.54%
Research & Development $98.10M $92.20M
YoY Change 37.59% 29.86%
% of Gross Profit 23.42% 23.97%
Depreciation & Amortization $51.00M $45.20M
YoY Change 91.73% 74.52%
% of Gross Profit 12.18% 11.75%
Operating Expenses $350.7M $336.5M
YoY Change 35.77% 32.32%
Operating Profit $68.10M $48.10M
YoY Change -45.3% -44.2%
Interest Expense -$9.200M -$24.20M
YoY Change -335.9% 178.16%
% of Operating Profit -13.51% -50.31%
Other Income/Expense, Net -$12.80M -$24.20M
YoY Change 141.51% 178.16%
Pretax Income $55.30M $23.90M
YoY Change -53.61% -69.16%
Income Tax $14.80M $16.10M
% Of Pretax Income 26.76% 67.36%
Net Earnings $40.90M $7.600M
YoY Change -53.58% -86.69%
Net Earnings / Revenue 4.73% 0.95%
Basic Earnings Per Share $0.27 $0.05
Diluted Earnings Per Share $0.27 $0.05
COMMON SHARES
Basic Shares Outstanding 151.4M 145.3M
Diluted Shares Outstanding 152.0 148.0

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.1M $169.7M
YoY Change -59.27% -70.48%
Cash & Equivalents $148.1M $169.7M
Short-Term Investments
Other Short-Term Assets $284.5M $300.2M
YoY Change 7.6% 23.49%
Inventory $1.220B $1.176B
Prepaid Expenses $35.60M $41.60M
Receivables $538.4M $507.2M
Other Receivables $66.80M $0.00
Total Short-Term Assets $2.191B $2.153B
YoY Change 7.98% -1.39%
LONG-TERM ASSETS
Property, Plant & Equipment $693.9M $656.6M
YoY Change 31.67% 25.62%
Goodwill $1.475B $1.444B
YoY Change 162.81% 158.79%
Intangibles $1.027B $1.024B
YoY Change 251.66% 240.98%
Long-Term Investments
YoY Change
Other Assets $238.1M $185.5M
YoY Change -41.96% -36.62%
Total Long-Term Assets $3.922B $3.750B
YoY Change 119.05% 124.03%
TOTAL ASSETS
Total Short-Term Assets $2.191B $2.153B
Total Long-Term Assets $3.922B $3.750B
Total Assets $6.113B $5.903B
YoY Change 60.04% 53.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $227.5M $220.3M
YoY Change 25.34% 16.68%
Accrued Expenses
YoY Change
Deferred Revenue $466.7M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $32.80M $26.40M
YoY Change -72.89% -78.16%
Total Short-Term Liabilities $1.322B $1.305B
YoY Change 23.3% 24.13%
LONG-TERM LIABILITIES
Long-Term Debt $2.265B $2.132B
YoY Change 106.13% 89.93%
Other Long-Term Liabilities $206.3M $641.6M
YoY Change -49.0% 52.4%
Total Long-Term Liabilities $2.471B $2.774B
YoY Change 64.38% 79.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.322B $1.305B
Total Long-Term Liabilities $2.471B $2.774B
Total Liabilities $4.270B $4.096B
YoY Change 65.79% 57.14%
SHAREHOLDERS EQUITY
Retained Earnings $2.401B $2.367B
YoY Change
Common Stock $704.1M $701.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.237B $1.237B
YoY Change 4.24% 11.74%
Treasury Stock Shares
Shareholders Equity $1.807B $1.807B
YoY Change
Total Liabilities & Shareholders Equity $6.113B $5.903B
YoY Change 60.04% 53.04%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $40.90M $7.600M
YoY Change -53.58% -86.69%
Depreciation, Depletion And Amortization $51.00M $45.20M
YoY Change 91.73% 74.52%
Cash From Operating Activities $38.40M $900.0K
YoY Change -12.93% -93.08%
INVESTING ACTIVITIES
Capital Expenditures $32.60M $26.00M
YoY Change 21.19% 10.64%
Acquisitions
YoY Change
Other Investing Activities -$35.00M -$1.299B
YoY Change -72.68% 51876.0%
Cash From Investing Activities -$67.60M -$1.325B
YoY Change -56.39% 4997.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.700M 1.157B
YoY Change -97.08% -11328.16%
NET CHANGE
Cash From Operating Activities 38.40M 900.0K
Cash From Investing Activities -67.60M -1.325B
Cash From Financing Activities -2.700M 1.157B
Net Change In Cash -31.90M -168.0M
YoY Change -84.32% 621.03%
FREE CASH FLOW
Cash From Operating Activities $38.40M $900.0K
Capital Expenditures $32.60M $26.00M
Free Cash Flow $5.800M -$25.10M
YoY Change -66.28% 139.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001109354
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 ecd Trd Arr Duration
TrdArrDuration
P294D
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-30833
dei Entity Registrant Name
EntityRegistrantName
BRUKER CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3110160
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Manning Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Billerica
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01821
dei City Area Code
CityAreaCode
978
dei Local Phone Number
LocalPhoneNumber
663-3660
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
BRKR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
151394441
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
169700000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
488300000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
507200000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
492000000
CY2024Q2 us-gaap Inventory Net
InventoryNet
1175900000
CY2023Q4 us-gaap Inventory Net
InventoryNet
968300000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
300200000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
215600000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
2153000000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2164200000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
656600000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
599700000
CY2024Q2 us-gaap Goodwill
Goodwill
1443800000
CY2023Q4 us-gaap Goodwill
Goodwill
582600000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1024300000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
330500000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
136200000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91700000
CY2024Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
303200000
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
297200000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
185500000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
184000000
CY2024Q2 us-gaap Assets
Assets
5902600000
CY2023Q4 us-gaap Assets
Assets
4249900000
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
26400000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121200000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
220300000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
202700000
CY2024Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
501900000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
400000000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
555900000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
478200000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1304500000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1202100000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2132000000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1160300000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
93900000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
91500000
CY2024Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
178500000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
67700000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
111300000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
74800000
CY2024Q2 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
79600000
CY2023Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
76600000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
178300000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
163600000
CY2024Q2 us-gaap Liabilities
Liabilities
4078100000
CY2023Q4 us-gaap Liabilities
Liabilities
2836600000
CY2024Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
17500000
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
18700000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
182170700
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
175943705
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
151391821
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145164826
CY2024Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1800000
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
30778879
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
30778879
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
1237200000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1237200000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
701300000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
282900000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2367300000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2323800000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-44000000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
6000000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
1789200000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1377200000
CY2024Q2 us-gaap Minority Interest
MinorityInterest
17800000
CY2023Q4 us-gaap Minority Interest
MinorityInterest
17400000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1807000000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1394600000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5902600000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4249900000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
800700000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
681900000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1522400000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1367200000
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
416100000
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
341400000
us-gaap Cost Of Revenue
CostOfRevenue
785000000
us-gaap Cost Of Revenue
CostOfRevenue
667000000
CY2024Q2 us-gaap Gross Profit
GrossProfit
384600000
CY2023Q2 us-gaap Gross Profit
GrossProfit
340500000
us-gaap Gross Profit
GrossProfit
737400000
us-gaap Gross Profit
GrossProfit
700200000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
221300000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
177900000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
416600000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
340600000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
92200000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
174000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
140000000
CY2024Q2 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
23000000
CY2023Q2 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
5400000
us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
33900000
us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
10700000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
336500000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
254300000
us-gaap Operating Expenses
OperatingExpenses
624500000
us-gaap Operating Expenses
OperatingExpenses
491300000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
48100000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
86200000
us-gaap Operating Income Loss
OperatingIncomeLoss
112900000
us-gaap Operating Income Loss
OperatingIncomeLoss
208900000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24200000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8700000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17400000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24800000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
23900000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
77500000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
95500000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
184100000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16100000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49800000
CY2024Q2 brkr Equity In Income Losses Of Unconsolidated Investees Net Of Tax
EquityInIncomeLossesOfUnconsolidatedInvesteesNetOfTax
-200000
CY2023Q2 brkr Equity In Income Losses Of Unconsolidated Investees Net Of Tax
EquityInIncomeLossesOfUnconsolidatedInvesteesNetOfTax
200000
brkr Equity In Income Losses Of Unconsolidated Investees Net Of Tax
EquityInIncomeLossesOfUnconsolidatedInvesteesNetOfTax
0
brkr Equity In Income Losses Of Unconsolidated Investees Net Of Tax
EquityInIncomeLossesOfUnconsolidatedInvesteesNetOfTax
900000
CY2024Q2 us-gaap Profit Loss
ProfitLoss
7600000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
57800000
us-gaap Profit Loss
ProfitLoss
59600000
us-gaap Profit Loss
ProfitLoss
135200000
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
700000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1100000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1600000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
7600000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
57100000
us-gaap Net Income Loss
NetIncomeLoss
58500000
us-gaap Net Income Loss
NetIncomeLoss
133600000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.91
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
147.4
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.8
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.3
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.8
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.7
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.6
CY2024Q2 us-gaap Profit Loss
ProfitLoss
7600000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
57800000
us-gaap Profit Loss
ProfitLoss
59600000
us-gaap Profit Loss
ProfitLoss
135200000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
2100000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
2200000
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
700000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28900000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
10300000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-106100000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
36100000
CY2024Q2 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
2300000
CY2023Q2 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
5000000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
-16800000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments Tax
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsTax
8300000
CY2024Q2 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
-7500000
CY2023Q2 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
-15900000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
54600000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
-26600000
CY2024Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
0
CY2023Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
200000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
0
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
600000
CY2024Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
100000
CY2023Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-700000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-500000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-800000
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-36500000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4900000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-51000000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
10300000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-28900000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
52900000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
8600000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
145500000
CY2024Q2 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
200000
CY2023Q2 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1300000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
1300000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
2600000
CY2024Q2 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-400000
CY2023Q2 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-300000
brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-1200000
brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-300000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28700000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
51900000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
8500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
143200000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1394600000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3400000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4600000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2024Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2024Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7300000
CY2024Q1 brkr Loans To Noncontrolling Interest
LoansToNoncontrollingInterest
900000
CY2024Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
52300000
CY2024Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-14000000
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1432900000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
500000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-100000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4800000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2100000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
403000000
CY2024Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2024Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7700000
CY2024Q2 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
7900000
CY2024Q2 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-36400000
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1807000000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1125700000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
700000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-100000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4100000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
22300000
CY2023Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
5300000
CY2023Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
77500000
CY2023Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
15100000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1198800000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
500000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4100000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1800000
CY2023Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q2 brkr Loans To Noncontrolling Interest
LoansToNoncontrollingInterest
300000
CY2023Q2 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
58200000
CY2023Q2 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-5000000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1250700000
us-gaap Profit Loss
ProfitLoss
59600000
us-gaap Profit Loss
ProfitLoss
135200000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
79900000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51000000
us-gaap Share Based Compensation
ShareBasedCompensation
12200000
us-gaap Share Based Compensation
ShareBasedCompensation
12100000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-22300000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
9400000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
21600000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
18300000
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
6800000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-800000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
9600000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
7100000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-16000000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-29500000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-30500000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
94000000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
114400000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
5600000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3400000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-22400000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-17800000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2100000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
21100000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
42600000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
41100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
22900000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
100500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48500000
brkr Proceeds From Disposal Of Minority Investment
ProceedsFromDisposalOfMinorityInvestment
0
brkr Proceeds From Disposal Of Minority Investment
ProceedsFromDisposalOfMinorityInvestment
-11800000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
10000000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
9300000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
1576500000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
102700000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
900000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10700000
us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-2500000
us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-3800000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1629100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-134200000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
840100000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
0
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1073300000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-10500000
us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-4500000
brkr Proceeds From2024 Note Purchase Agreements
ProceedsFrom2024NotePurchaseAgreements
472100000
brkr Proceeds From2024 Note Purchase Agreements
ProceedsFrom2024NotePurchaseAgreements
0
brkr Proceeds From2024 Term Loan Agreements
ProceedsFrom2024TermLoanAgreements
329500000
brkr Proceeds From2024 Term Loan Agreements
ProceedsFrom2024TermLoanAgreements
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4100000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2800000
brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
-100000000
brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
0
brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-7500000
brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-7500000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5500000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
402900000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5700000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2800000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
500000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2500000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
15000000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
14700000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
22400000
us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
-1000000
us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
5000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1307500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-41000000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-19700000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4200000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-318400000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-70500000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
491600000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
648700000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
173200000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
578200000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3300000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3200000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3400000
us-gaap Nature Of Operations
NatureOfOperations
<div class="item-list-element-wrapper" style="display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI Nano and Bruker Energy &amp; Supercon Technologies (BEST).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI BioSpin Segment designs, manufactures and distributes enabling life science tools based on magnetic resonance technology and provides laboratory automation and quality control workflow solutions in a wide range of chemical research fields. BSI BioSpin Segment’s revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI CALID Segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies, molecular diagnostics, microbiology and biomedical testing equipment, and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the BSI CALID Segment include academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI Nano Segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; spark optical emission spectroscopy systems; chipcytometry products and services for targeted spatial proteomics, multi-omic services; optofluidic and proteomic barcoding platforms; and products and services for spatial genomics research. Customers of the BSI Nano Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BEST Segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of June 30, 2024, and December 31, 2023, and for the three and six months ended June 30, 2024, and 2023, have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, the financial information presented herein does not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024, the Company’s significant accounting policies as detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, have not changed. Effective in the quarter ended June 30, 2024, the Company entered into a multi-currency notional cash pooling agreement with a financial institution to manage cash flow more efficiently and optimize liquidity. Additionally, the Company added applicable revenue recognition policy updates relevant to recent acquisitions. Accounting policies adopted relevant to these activities are described in the following paragraphs</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Multi-Currency Notional Cash Pooling Policy</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Effective during the quarter ended June 30, 2024, the Company entered into a master netting arrangement with a third-party financial institution whereby certain subsidiaries participate in a notional cash pooling arrangement to manage global liquidity requirements. As part of the master netting arrangement, the participating subsidiaries combine their cash balances in pooling accounts at the same financial institution with the ability to offset bank overdrafts of one participant against positive cash account balances held by another participant. Under the terms of the master netting arrangement, the financial institution has the right, ability, and intent to offset a positive balance in one account against an overdrawn amount in another account. Amounts in each of the accounts are unencumbered and unrestricted with respect to use. As such, the net positive cash balance related to this pooling arrangement is included in cash, and cash equivalents in the consolidated balance sheets. The notional cash pool runs daily on a net positive cash basis and is not intended to be used as a source of funding. In the event there is a one-day net overdraft due to the timing of bank postings, the overdraft would represent a short-term loan from the bank and would be classified as current debt on the consolidated balance sheets and financing cash flows in the consolidated statement of cash flows. As of June 30, 2024, the Company was not in a net overdraft position with respect to the notional cash pooling arrangement.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue Recognition Policy</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenues from instrument rental and reagent agreements provide customers with the right to use the Company’s instruments upon entering into multi-year agreements to purchase annual minimum amounts of reagents. These types of agreements include an embedded lease relating to the customer’s right to use the Company’s instruments over the period of the agreement. The agreement transaction price is allocated between the instrument and the reagents based on their relative standalone selling prices. When collectability of payments due is probable, reagent rental programs that effectively transfer control of instruments to customers are classified as sales-type leases and instrument revenue and cost of revenue are recognized upon the transfer of control to the customer which is often in advance of billings to the customer. The Company’s right to future consideration from reagent purchases under the agreement is allocated to instrument revenue and is recorded as a lease receivable within other current and long-term assets. Revenues from instrument rental and reagent agreements where collectability of payments due is not probable or that do not transfer control of the instruments to customers are classified as operating leases and instrument revenue and costs of revenue are recognized over the term of the agreement. The cost of the instrument is capitalized as a long-term asset and depreciated to cost of revenues. Lease revenues from these agreements are presented in product revenue in the consolidated statement of income.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to the same risks and uncertainties as disclosed in its Annual Report on Form 10-K filed with the SEC on February 29, 2024, however, as of January 1, 2024, the Company is subject to new risks related to its self-funded health insurance. Effective January 1, 2024, the Company is self-insured for health care claims for eligible participating U.S. employees subject to certain deductibles and limitations. The Company determines its liability for claims incurred but not reported for insurance liabilities on an actuarial basis. Since there are many estimates and assumptions involved in recording insurance liabilities, differences between actual future events and prior estimates and assumptions, could result in materially different amounts of expense and result in adjustments to these liabilities and materially different amounts of expense, which could harm our business and adversely affect our results of operations and financial condition.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the global supply chain interruptions, higher energy costs and shortages, increased costs of and delivery times for critical raw materials, the global economy, including inflation and the threat of recession, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee cost related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning global supply chain and various global conflicts. The Company has made estimates of the impact of these disruptions within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the global supply chain interruptions, higher energy costs and shortages, increased costs of and delivery times for critical raw materials, the global economy, including inflation and the threat of recession, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee cost related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning global supply chain and various global conflicts. The Company has made estimates of the impact of these disruptions within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.</span>
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
800700000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
681900000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1522400000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1367200000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
800700000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
681900000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1522400000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1367200000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
800700000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
681900000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1522400000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1367200000
CY2024Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2257700000
CY2024Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
103600000
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
85800000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
595800000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
491400000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
227700000
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
420600000
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
371200000
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
383800000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
314900000
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
265600000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
183900000
CY2024Q2 us-gaap Other Inventory Demo
OtherInventoryDemo
105900000
CY2023Q4 us-gaap Other Inventory Demo
OtherInventoryDemo
98300000
CY2024Q2 us-gaap Inventory Net
InventoryNet
1175900000
CY2023Q4 us-gaap Inventory Net
InventoryNet
968300000
CY2024Q2 us-gaap Other Inventory In Transit
OtherInventoryInTransit
57100000
CY2023Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
48600000
CY2024Q2 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
99800000
CY2023Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
83900000
CY2024Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
87300000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
45900000
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
41600000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
26700000
CY2024Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
32100000
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
28800000
CY2024Q2 us-gaap Asset Reporting Currency Denominated Value
AssetReportingCurrencyDenominatedValue
12700000
CY2023Q4 us-gaap Asset Reporting Currency Denominated Value
AssetReportingCurrencyDenominatedValue
12000000
CY2024Q2 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
26700000
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
18300000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
300200000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
215600000
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
1626100000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
52100000
CY2024Q2 us-gaap Business Combination Contingent Consideration Asset
BusinessCombinationContingentConsiderationAsset
13400000
brkr Business Combination Consideration Transferred Working Capital Adjustment
BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment
-25600000
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
57300000
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
161200000
CY2024Q2 brkr Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets
27100000
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
69800000
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
82300000
CY2024Q2 us-gaap Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital
DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital
-112200000
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
292000000
CY2024Q2 us-gaap Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
1613000000
CY2024Q2 brkr Net Increase Decrease In Amortization And Depreciation Expense Of Tangible And Intangible Assets
NetIncreaseDecreaseInAmortizationAndDepreciationExpenseOfTangibleAndIntangibleAssets
7600000
CY2023Q2 brkr Net Increase Decrease In Amortization And Depreciation Expense Of Tangible And Intangible Assets
NetIncreaseDecreaseInAmortizationAndDepreciationExpenseOfTangibleAndIntangibleAssets
14900000
brkr Net Increase Decrease In Amortization And Depreciation Expense Of Tangible And Intangible Assets
NetIncreaseDecreaseInAmortizationAndDepreciationExpenseOfTangibleAndIntangibleAssets
25800000
CY2023Q2 us-gaap Interest Expense Interest Bearing Liability Increase Decrease
InterestExpenseInterestBearingLiabilityIncreaseDecrease
-15000000
us-gaap Interest Expense Interest Bearing Liability Increase Decrease
InterestExpenseInterestBearingLiabilityIncreaseDecrease
-10000000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
114100000
brkr Payments To Acquire Businesses Cash Acquired
PaymentsToAcquireBusinessesCashAcquired
106200000
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
20200000
CY2024Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
20200000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
26700000
brkr Payments To Acquire Businesses Cash Acquired
PaymentsToAcquireBusinessesCashAcquired
19800000
us-gaap Gain Loss On Disposition Of Other Financial Assets
GainLossOnDispositionOfOtherFinancialAssets
6800000
CY2023Q2 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
11400000
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
18300000
CY2023Q4 us-gaap Goodwill
Goodwill
582600000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
876100000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-14900000
CY2024Q2 us-gaap Goodwill
Goodwill
1443800000
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1412300000
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
388000000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1024300000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
686300000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
355800000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
330500000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
25100000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11200000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
41300000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
21900000
CY2024Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3400000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1300000
CY2024Q2 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
2140000000
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1260600000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
2158400000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
1281500000
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
26400000
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121200000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2132000000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1160300000
CY2024Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
1056200000
us-gaap Line Of Credit Facility Maximum Amount Outstanding During Period
LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
222600000
CY2024Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
156500000
CY2024Q2 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
677100000
CY2024Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
230000000
CY2024Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
269000000
CY2024Q2 us-gaap Foreign Currency Contracts Liability Fair Value Disclosure
ForeignCurrencyContractsLiabilityFairValueDisclosure
0
CY2024Q2 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
1236500000
CY2023Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
883300000
CY2024Q2 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
2568200000
CY2024Q2 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-19500000
CY2023Q4 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1777900000
CY2023Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
-89600000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16100000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
19900000
CY2024Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.674
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.257
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49800000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.376
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.271
CY2024Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
69400000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
58500000
CY2024Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
4300000
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
5800000
CY2024Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
-3400000
CY2023Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
200000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
-2200000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
600000
us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.045
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7600000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
57100000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
58500000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
133600000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
147.4
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.8
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.3
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.8
CY2024Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.6
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.9
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.7
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.8
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.7
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.6
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.39
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.91
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
CY2022Q3 brkr Excise Tax On Stock Repurchases
ExciseTaxOnStockRepurchases
0.01
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5100000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4400000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10000000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8700000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5100000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4400000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10000000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8700000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
CY2024Q2 brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
1900000
CY2023Q2 brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
600000
brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
2700000
brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
1100000
CY2024Q2 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
1200000
CY2023Q2 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
300000
brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
4700000
brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
600000
CY2024Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
17500000
CY2023Q2 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
2900000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
21600000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5800000
CY2024Q2 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
2400000
CY2023Q2 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
1600000
brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
4900000
brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
3200000
CY2024Q2 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
23000000
CY2023Q2 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
5400000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
33900000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
10700000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
6100000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
400000
us-gaap Restructuring Charges
RestructuringCharges
13300000
us-gaap Restructuring Charges
RestructuringCharges
900000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
13100000
us-gaap Restructuring Charges
RestructuringCharges
13300000
us-gaap Payments For Restructuring
PaymentsForRestructuring
14400000
us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
-5600000
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
6400000
CY2024Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
300000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
1500000
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
7200000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2400000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1900000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5000000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3300000
CY2024Q2 us-gaap Interest Expense
InterestExpense
15700000
CY2023Q2 us-gaap Interest Expense
InterestExpense
3900000
us-gaap Interest Expense
InterestExpense
20700000
us-gaap Interest Expense
InterestExpense
8100000
CY2024Q2 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
20200000
CY2023Q2 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
11400000
us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
20200000
us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
18300000
CY2024Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
9000000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2200000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
17900000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5500000
CY2024Q2 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
-300000
CY2023Q2 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
0
us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
-600000
us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
100000
CY2024Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
6900000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3900000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24200000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8700000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17400000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24800000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
17900000
CY2024Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2000000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
48100000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
86200000
us-gaap Operating Income Loss
OperatingIncomeLoss
112900000
us-gaap Operating Income Loss
OperatingIncomeLoss
208900000
CY2024Q2 us-gaap Assets
Assets
5902600000
CY2023Q4 us-gaap Assets
Assets
4249900000
CY2024Q2 ecd Trd Arr Adoption Date
TrdArrAdoptionDate
March 11, 2024
CY2024Q2 ecd Trd Arr Ind Name
TrdArrIndName
Dr. Cynthia Friend
CY2024Q2 ecd Trd Arr Ind Title
TrdArrIndTitle
Board of Directors
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
true
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2024Q2 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
1785
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
true
CY2024Q2 ecd Trd Arr Termination Date
TrdArrTerminationDate
December 31, 2024

Files In Submission

Name View Source Status
0000950170-24-094832-index-headers.html Edgar Link pending
0000950170-24-094832-index.html Edgar Link pending
0000950170-24-094832.txt Edgar Link pending
0000950170-24-094832-xbrl.zip Edgar Link pending
brkr-20240630.htm Edgar Link pending
brkr-20240630.xsd Edgar Link pending
brkr-ex10_2.htm Edgar Link pending
brkr-ex10_3.htm Edgar Link pending
brkr-ex31_1.htm Edgar Link pending
brkr-ex31_2.htm Edgar Link pending
brkr-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
brkr-20240630_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable